Drug delivery to the posterior segment of the eye for pharmacologic therapy

Expert Review of Ophthalmology

Volumn 5, Issue 1, 2010, Pages 75-93

  Shah, shalin S ^a   Denham, Lori Vidal ^b   Elison, Jasmine R ^a   Bhattacharjee, Partha S ^c   Huq, Tashfin ^c   Clement, Christian ^a   Hill, James M ^d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tulane University   (United States)

^c UNIVERSITY OF LOUISIANA   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

biodegradable; drug delivery; intravitreal; iontophoresis; microbubbles; microspheres; nonbiodegradable; subconjunctival; sustained release; transscleral

Indexed keywords

EID: 79952236067     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.09.70     Document Type: Article

References (145)

1. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res. 41, 124–135 (2009).
2. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr. Drug Deliv. 3, 207–217 (2006).
3. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. Int. Ophthalmol. Clin. 44, 33–39 (2004).
4. Barocas VH, Balachandran RK. Sustained transscleral drug delivery. Expert Opin. Drug Deliv. 5, 1–10 (2008).
5. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior egment. Drug Discov. Today 13, 135–143 (2008).
6. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm. Res. 26, 1197–1216 (2009).
7. Hsu J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol. 18, 235–239 (2007).
8. Hoffman AS. The origins and evolution of ‘controlled’ drug delivery systems. J. Control. Release 132, 153–163 (2008).
9. Novack GD. Ophthalmic drug delivery: development and regulatory considerations. Clin. Pharmacol. Ther. 85, 539–543 (2009).
10. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin. Drug Deliv. 5, 567–581 (2008).
11. Liu M, Regillo CD. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Curr. Opin. Ophthalmol. 15, 221–226 (2004).
12. Booth BA, Denham LV, Bouhanik S, acob JT, Hill JM. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 24, 581–602 (2007).
13. Bekeredjian R, Katus HA, Kuecherer HF. Therapeutic use of ultrasound targeted microbubble destruction: a review of non-cardiac applications. Ultraschall. Med. 27, 134–140 (2006).
14. Gershkovich P, Wasan KM, Barta CA. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 25, 545–584 (2008).
15. Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina 27, 662–680 (2007).
16. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr. Opin. Ophthalmol. 18, 502–508 (2007).
17. Mitra AK. Role of transporters in ocular drug delivery system. Pharm. Res. 26, 1192–1196 (2009).
18. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin. Drug Deliv. 3, 275–287 (2006).
19. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58, 1131–1135 (2006).
20. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4, 371–388 (2007).
21. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65, 859–878 (2005).
22. Chen KJ, Hwang YS, Chen YP, Lai CC, Chen TL, Wang NK. Endogenous Klebsiella endophthalmitis associated with Klebsiella pneumoniae pneumonia. Ocul. Immunol. Inflamm. 17, 153–159 (2009).
23. Hori Y, Nakazawa T, Maeda N et al. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones. J. Cataract Refract. Surg. 35, 475–479 (2009).
24. Keating GM. Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. Drugs 69, 1267–1286 (2009).
25. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 39, 244–254 (2007).
26. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther. 20, 43–53 (2004).
27. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J. Ocul. Pharmacol. Ther. 20, 55–64 (2004).
28. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J. Ocul. Pharmacol. Ther. 17, 565–572 (2001).
29. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection. J. Ocul. Pharmacol. Ther. 25, 29–37 (2009).
30. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 36, 1893–1903 (1995).
31. Ambati J, Canakis CS, Miller JW et al. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41, 1181–1185 (2000).
32. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 57, 2063–2079 (2005).
33. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57, 2010–2032 (2005).
34. Hayden B, Jockovich ME, Murray TG et al. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Invest. Ophthalmol. Vis. Sci. 47, 3713–3721 (2006).
35. Frucht-Pery J, Mechoulam H, Siganos CS, Ever-Hadani P, Shapiro MN, Domb A. Iontophoresis–gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe. Exp. Eye Res. 78, 745–749 (2004).
36. Eljarrat-Binstock E, Raiskup F, Stepensky D, Domb AJ, Frucht-Pery J. Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest. Ophthalmol. Vis. Sci. 45, 2543–2548 (2004).
37. Bochot A, Fattal E, Boutet V et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Vis. Sci. 43, 253–259 (2002).
38. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N. Engl. J. Med. 337, 83–90 (1997).
39. Martin DF, Parks DJ, Mellow SD et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112, 1531–1539 (1994).
40. Lim JI, Wolitz RA, Dowling AH, Bloom HR, Irvine AR, Schwartz DM. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 127, 288–293 (1999).
41. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112, 1192–1198 (2005).
42. Callanan DG, Jaffe GJ, Martin DF et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol. 126, 1191–1201 (2008).
43. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113, 1020–1027 (2006).
44. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin. Drug Deliv. 5, 1039–1046 (2008).
45. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am. J. Ophthalmol. 146, 285–291 (2008).
46. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm. Res. 26, 770–784 (2009).
47. Ciulla TA, Criswell MH, Danis RP et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 87, 1032–1037 (2003).
48. Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr. Opin. Ophthalmol. 15, 211–220 (2004).
49. Beeley NR, Stewart JM, Tano R et al. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J. Biomed. Mater. Res. A 76, 690–698 (2006).
50. Beeley NR, Rossi JV, Mello-Filho PA et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J. Biomed. Mater. Res. A 73, 437–444 (2005).
51. Kim S, Kim JH, Jeon O, Kwon IC, Park K. Engineered polymers for advanced drug delivery. Eur. J. Pharm. Biopharm. 71, 420–430 (2009).
52. Williams GA, Haller JA, Kuppermann BD et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irving–Gass syndrome. Am. J. Ophthalmol. 147, 1048–1054.e2 (2009).
53. Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125, 309–317 (2007).
54. Bourges JL, Gautier SE, Delie F et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44, 3562–3569 (2003).
55. Bu HZ, Gukasyan HJ, Goulet L et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Metab. 8, 91–107 (2007).
56. Guidetti B, Azema J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr. Drug Deliv. 5, 7–19 (2008).
57. Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Rev. Med. Devices 6 (3), 277–290 (2009).
58. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 23, 253–281 (2004).
59. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52, 37–48 (2001).
60. Kashyap N, Modi S, Jain JP et al. Polymers for advanced drug delivery. CRIPS (Current Research & Information on Pharmaceutical Science) 5, 7–12 (2004).
61. Kranz H, Ubrich N, Maincent P, Bodmeier R. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. J. Pharm. Sci. 89, 1558–1566 (2000).
62. Moinard-Checot D, Chevalier Y, Briancon S, Beney L, Fessi H. Mechanism of nanocapsules formation by the emulsion–diffusion process. J. Colloid Interface Sci. 317, 458–468 (2008).
63. Moinard-Checot D, Chevalier Y, Briancon S, Fessi H, Guinebretiere S. Nanoparticles for drug delivery: review of the formulation and process difficulties illustrated by the emulsion–diffusion process. J. Nanosci. Nanotechnol. 6, 2664–2681 (2006).
64. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364, 298–327 (2008).
65. Moritera T, Ogura Y, Yoshimura N et al. Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Curr. Eye Res. 13, 171–176 (1994).
66. Kimura H, Ogura Y, Moritera T, Honda Y, Tabata Y, Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr. Eye Res. 13, 353–360 (1994).
67. Tuovinen L, Ruhanen E, Kinnarinen T et al. Starch acetate microparticles for drug delivery into retinal pigment epithelium– In vitro study. J. Control. Release 98, 407–413 (2004).
68. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 3, 31–36 (2001).
69. Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 26, 329–337 (2009).
70. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44, 1192–1201 (2003).
71. Loftsson T, Hreinsdottir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J. Pharm. Pharmacol. 59, 629–635 (2007).
72. Gomez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 331, 153–159 (2007).
73. Gomez-Gaete C, Fattal E, Silva L, Besnard M, Tsapis N. Dexamethasone acetate encapsulation into Trojan particles. J. Control. Release. 128, 41–49 (2008).
74. Veloso AA Jr, Zhu Q, Herrero-Vanrell R, Refojo MF. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. 38, 665–675 (1997).
75. Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, Refojo MF. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm. Res. 17, 1323–1328 (2000).
76. Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23, 1587–1594 (2002).
77. Irache JM, Merodio M, Arnedo A, Camapanero A, Mirshahi M, Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini. Rev. Med. Chem. 53 (2), 293–305 (2005).
78. Duvvuri S, Gaurav Janoria K, Mitra AK. Effect of polymer blending on the release of ganciclovir from PLGA microspheres. Pharm. Res. 23, 215–223 (2006).
79. Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly(D,L-lactide-co-glycolide) microspheres dispersed in PLGA–PEG–PLGA gel for sustained delivery of ganciclovir. J. Control. Release. 108, 282–293 (2005).
80. Duvvuri S, Janoria KG, Pal D, Mitra AK. Controlled delivery of ganciclovir to the retina with drug-loaded poly(D,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA–PEG–PLGA gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J. Ocul. Pharmacol. Ther. 23, 264–274 (2007).
81. Duvvuri S, Rittenhouse KD, Mitra AK. Microdialysis assessment of drug delivery systems for vitreoretinal targets. Adv. Drug Deliv. Rev. 57, 2080–2091 (2005).
82. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. Int. J. Pharm. 326, 100–106 (2006).
83. Cortesi R, Ajanji SC, Sivieri E et al. Eudragit microparticles as a possible tool for ophthalmic administration of acyclovir. J. Microencapsul. 24, 445–456 (2007).
84. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. 32, 1785–1790 (1991).
85. Moritera T, Ogura Y, Yoshimura N et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 33, 3125–3130 (1992).
86. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. 34, 2743–2751 (1993).
87. Peyman GA, Conway M, Khoobehi B, Soike K. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. 16, 109–113 (1992).
88. Yeh MK, Tung SM, Lu DW, Chen JL, Chiang CH. Formulation factors for preparing ocular biodegradable delivery system of 5-fluorouracil microparticles. J. Microencapsul. 18, 507–519 (2001).
89. de Kozak Y, Andrieux K, Villarroya H et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34, 3702–3712 (2004).
90. He Y, Liu Y, Liu Y et al. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. Invest. Ophthalmol. Vis. Sci. 47, 3983–3988 (2006).
91. Sakai T, Kohno H, Ishihara T et al. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating β-methasone phosphate. Exp. Eye Res. 82, 657–663 (2006).
92. Barcia E, Herrero-Vanrell R, Diez A, Alvarez-Santiago C, Lopez I, Calonge M. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp. Eye Res. 89, 238–245 (2009).
93. Chen J, Patil S, Seal S, McGinnis JF. Nanoceria particles prevent ROI-induced blindness. Adv. Exp. Med. Biol. 613, 53–59 (2008).
94. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat. Nanotechnol. 1, 142–150 (2006).
95. Edelhauser HF, Boatright JH, Nickerson JM. Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 49, 4712–4720 (2008).
96. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB. J. 16, 1217–1226 (2002).
97. Bejjani RA, BenEzra D, Cohen H et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11, 124–132 (2005).
98. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vis. 13, 746–757 (2007).
99. Fattal E, Bochot A. Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseases. Arch. Soc. Esp. Oftalmol. 81, 3–6 (2006).
100. Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest. Ophthalmol. Vis. Sci. 48, 1900–1905 (2007).
101. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm. 364, 237–248 (2008).
102. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J. Pharm. Pharmacol. 55, 1199–1206 (2003).
103. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. 44, 290–299 (2003).
104. Moshfeghi AA, Peyman GA. Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 57, 2047–2052 (2005).
105. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16, 645–659 (2009).
106. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 57, 1555–1563 (2005).
107. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 14, 150–160 (2008).
108. Chiang CH, Tung SM, Lu DW, Yeh MK. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J. Ocul. Pharmacol. Ther. 17, 545–553 (2001).
109. Saishin Y, Silva RL, Saishin Y et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44, 4989–4993 (2003).
110. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458, 283–289 (2003).
111. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 21, 1797–1804 (2004).
112. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib–PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511, 191–198 (2005).
113. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib–PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47, 1149–1160 (2006).
114. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52, 5–16 (2001).
115. Tinkov S, Bekeredjian R, Winter G, Coester C. Microbubbles as ultrasound triggered drug carriers. J. Pharm. Sci. 98, 1935–1961 (2009).
116. Porter TR, Cwajg JM. Contrast echocardiography. In: Imaging in Cardiovascular Disease. Prohost GM (Ed.). Lippincott Williams & Wilkins, PA, USA, 85–96 (2000).
117. Qin L, Pahud DR, Ding Y et al. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Hum. Gene Ther. 9, 553–560 (1998).
118. Kost J, Leong K, Langer R. Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc. Natl Acad. Sci. USA 86, 7663–7666 (1989).
119. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med. Biol. 23, 953–959 (1997).
120. Huber PE, Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 7, 1516–1525 (2000).
121. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. Ultrasound-mediated transfection of mammalian cells. Hum. Gene Ther. 7, 1339–1346 (1996).
122. Miller DL, Bao S, Gies RA, Thrall BD. Ultrasonic enhancement of gene transfection in murine melanoma tumors. Ultrasound Med. Biol. 25, 1425–1430 (1999).
123. Tata DB, Dunn F, Tindall DJ. Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem. Biophys. Res. Commun. 234, 64–67 (1997).
124. Mukherjee D, Wong J, Griffin B et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J. Am. Coll. Cardiol. 35, 1678–1686 (2000).
125. Zderic V, Clark JI, Vaezy S. Drug delivery into the eye with the use of ultrasound. J. Ultrasound Med. 23, 1349–1359 (2004).
126. Price RJ, Kaul S. Contrast ultrasound targeted drug and gene delivery: an update on a new therapeutic modality. J. Cardiovasc. Pharmacol. Ther. 7, 171–180 (2002).
127. Kooiman K, Bohmer MR, Emmer M et al. Oil-filled polymer microcapsules for ultrasound-mediated delivery of lipophilic drugs. J. Control. Release. 133, 109–118 (2009).
128. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T. Local drug and gene delivery through microbubbles. Prog. Cardiovasc. Dis. 44, 45–54 (2001).
129. Unger EC, Matsunaga TO, McCreery T, Schumann P, Sweitzer R, Quigley R. Therapeutic applications of microbubbles. Eur. J. Radiol. 42, 160–168 (2002).
130. Tsutsui JM, Grayburn PA, Xie F, Porter TR. Drug and gene delivery and enhancement of thrombolysis using ultrasound and microbubbles. Cardiol. Clin. 22, 299–312 vii (2004).
131. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat. Rev. Drug Discov. 4, 255–260 (2005).
132. Lawrie A, Brisken AF, Francis SE, Cumberland DC, Crossman DC, Newman CM. Microbubble-enhanced ultrasound for vascular gene delivery. Gene Ther. 7, 2023–2027 (2000).
133. Postema M, Gilja OH. Ultrasound-directed drug delivery. Curr. Pharm. Biotechnol. 8, 355–361 (2007).
134. Mayer CR, Geis NA, Katus HA, Bekeredijan R. Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin. Drug Deliv. 5, 1121–1138 (2008).
135. Shimamura M, Sato N, Taniyama Y et al. Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound. Gene Ther. 11, 1532–1539 (2004).
136. Hirokawa T, Karshafian R, Pavlin CJ, Burns PN. Insonation of the eye in the presence of microbubbles: preliminary study of the duration and degree of vascular bioeffects – work in progress. J. Ultrasound Med. 26, 731–738 (2007).
137. Sonoda S, Tachibana K, Uchino E et al. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Invest. Ophthalmol. Vis. Sci. 47, 558–564 (2006).
138. Peeters L, Lentacker I, Vandenbroucke RE et al. Can ultrasound solve the transport barrier of the neural retina? Pharm. Res. 25, 2657–2665 (2008).
139. Church CC. The effects of an elastic solid surface layer on the radial pulsations of gas bubbles. J. Acoust. Soc. Am. 97, 1510–1521 (1995).
140. Hoff L, Sontum PC, Hovem JM. Oscillations of polymeric microbubbles: effect of the encapsulating shell. J. Acoust. Soc. Am. 107, 2272–2280 (2000).
141. Shankar PM, Krishna PD, Newhouse VL. Subharmonic backscattering from ultrasound contrast agents. J. Acoust. Soc. Am. 106, 2104–2110 (1999).
142. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans. Am. Ophthalmol. Soc. 106, 206–213 (2008).
143. Lin CC, Metters AT. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Del. Rev. 58, 1379–1408 (2006).
144. Zhang XZ, Yang YY, Chung TS, Ma KX. Preparation and characterization of fast response macroporous poly(N-isopropylacrylamide) hydrogels. Langmuir 17, 6094–6099 (2001).
145. Southern Illinois University School of Medicine www.siumed.edu/yoc/